$1.27
6.30% today
Nasdaq, Sep 03, 09:47 pm CET
ISIN
US19249H1032
Symbol
CHRS

Coherus BioSciences, Inc. Stock price

$1.19
+0.32 37.10% 1M
+0.19 18.41% 6M
-0.19 13.77% YTD
-0.20 14.39% 1Y
-9.01 88.33% 3Y
-17.88 93.76% 5Y
-26.49 95.70% 10Y
-11.42 90.56% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
+0.03 2.59%
ISIN
US19249H1032
Symbol
CHRS
Industry

Key metrics

Basic
Market capitalization
$138.3m
Enterprise Value
$-49.4m
Net debt
positive
Cash
$237.6m
Shares outstanding
116.2m
Valuation (TTM | estimate)
P/E
0.8 | negative
P/S
1.0 | 2.9
EV/Sales
negative | negative
EV/FCF
0.5
P/B
1.2
Financial Health
Equity Ratio
-29.4%
Return on Equity
-21.6%
ROCE
-80.0%
ROIC
-233.7%
Debt/Equity
0.4
Financials (TTM | estimate)
Revenue
$142.8m | $47.4m
EBITDA
$-136.1m | $-147.6m
EBIT
$-140.7m | $-157.5m
Net Income
$179.8m | $-145.2m
Free Cash Flow
$-105.9m
Growth (TTM | estimate)
Revenue
-53.7% | -82.3%
EBITDA
8.5% | -58.9%
EBIT
8.2% | -60.4%
Net Income
713.5% | -609.4%
Free Cash Flow
-94.9%
Margin (TTM | estimate)
Gross
57.5%
EBITDA
-95.3% | -311.5%
EBIT
-98.6%
Net
125.9% | -306.4%
Free Cash Flow
-74.2%
More
EPS
$1.5
FCF per Share
$-0.9
Short interest
29.3%
Employees
228
Rev per Employee
$1.2m
Show more

Is Coherus BioSciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Coherus BioSciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Coherus BioSciences, Inc. forecast:

9x Buy
75%
3x Hold
25%

Analyst Opinions

12 Analysts have issued a Coherus BioSciences, Inc. forecast:

Buy
75%
Hold
25%

Financial data from Coherus BioSciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
143 143
54% 54%
100%
- Direct Costs 61 61
66% 66%
42%
82 82
36% 36%
58%
- Selling and Administrative Expenses 121 121
32% 32%
85%
- Research and Development Expense 94 94
9% 9%
66%
-136 -136
8% 8%
-95%
- Depreciation and Amortization 4.64 4.64
1% 1%
3%
EBIT (Operating Income) EBIT -141 -141
8% 8%
-99%
Net Profit 180 180
713% 713%
126%

In millions USD.

Don't miss a Thing! We will send you all news about Coherus BioSciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Coherus BioSciences, Inc. Stock News

Positive
Seeking Alpha
9 days ago
Coherus Oncology remains a speculative play, with a strong cash position post-Udenyca sale and a cash runway into 2026 supporting ongoing pipeline development. Toripalimab sales are steady but limited by a small patient population, so financial viability hinges on the success of novel pipeline agents like casdozokitug and CHS-114. Pipeline risks are significant, as neither IL-27 nor CCR8 target...
Neutral
Seeking Alpha
25 days ago
Coherus Oncology, Inc. (NASDAQ:CHRS ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Bryan J. McMichael - Chief Financial Officer Dennis M.
Positive
The Motley Fool
27 days ago
Coherus (CHRS) Q2 Revenue Jumps 10%
More Coherus BioSciences, Inc. News

Company Profile

Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Head office United States
CEO Denny Lanfear
Employees 228
Founded 2010
Website www.coherus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today